MedTrace Logo

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2022-09-16

No results posted yet for this study

Summary

This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

HPG1860

The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.

DRUG

Placebo

Capsule

Sponsors & Collaborators

  • Hepagene (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Naim Alkhouri · Arizona Liver Health - Tucson

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-22
Primary Completion
2023-02-28
Completion
2023-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05338034 on ClinicalTrials.gov